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ABSTRACT
Transmembrane sodium (Naþ) fluxes and intracellular sodium homeostasis are central players in the
physiology of the cardiac myocyte, since they are crucial for both cell excitability and for the regulation
of the intracellular calcium concentration. Furthermore, Naþ fluxes across the membrane of
mitochondria affect the concentration of protons and calcium in the matrix, regulating mitochondrial
function. In this review we first analyze the main molecular determinants of sodium fluxes across the
sarcolemma and the mitochondrial membrane and describe their role in the physiology of the healthy
myocyte. In particular we focus on the interplay between intracellular Ca2þ and Naþ. A large part of the
review is dedicated to discuss the changes of Naþ fluxes and intracellular Naþ concentration([Naþ]i)
occurring in cardiac disease; we specifically focus on heart failure and hypertrophic cardiomyopathy,
where increased intracellular [Naþ]i is an established determinant of myocardial dysfunction. We
review experimental evidence attributing the increase of [Naþ]i to either decreased Na
þ efflux (e.g. via
the Naþ/Kþ pump) or increased Naþ influx into the myocyte (e.g. via Naþ channels). In particular, we
focus on the role of the “late sodium current” (INaL), a sustained component of the fast Na
þ current of
cardiac myocytes, which is abnormally enhanced in cardiac diseases and contributes to both electrical
and contractile dysfunction. We analyze the pathophysiological role of INaL enhancement in heart
failure and hypertrophic cardiomyopathy and the consequences of its pharmacological modulation,
highlighting the clinical implications.
The central role of Naþ fluxes and intracellular Naþ physiology and pathophysiology of cardiac
myocytes has been highlighted by a large number of recent works. The possibility of modulating Naþ
inward fluxes and [Naþ]i with specific INaL inhibitors, such as ranolazine, has made Na
þa novel suitable
target for cardiac therapy, potentially capable of addressing arrhythmogenesis and diastolic
dysfunction in severe conditions such as heart failure and hypertrophic cardiomyopathy.
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Sodium (Naþ) is the principal cation in the extracellular milieau and its highly regulated movement
across the membrane of cardiac myocytes is the primary determinant of action potential (AP)
upstroke and is essential for autoregenerative impulse propagation throughout the myocardium. In
order to support cell excitability a large Naþ gradient across the membrane needs to be maintained.
Thus intracellular sodium concentration ([Na2þ]i) within the cardiac myocyte must be accurately
controlled and is finely regulated by a number of channels and transporters.1 Despite that Naþ has
been classically seen solely as a regulator of cardiac excitability, [Na2þ]i is an important modulator
of numerous aspects of cardiomyocyte function, from excitation-contraction coupling to energy
production and consumption. In fact, [Na2þ]i is a major determinant of the intracellular
concentrations of Ca2þ([Ca2þ]i), as well as other ions and molecules. Moreover [Na
2þ]i strictly
regulates the concentration of Ca2þ within the mitochondria, a major determinant of the rate of ATP
production and the generation of reactive oxygen species (ROS). Great interest has been recently
devoted to the study of Naþ homeostasis since [Na2þ]i can be dysregulated in cardiac disease and
its dysregulation may strongly contribute to their pathophysiology. As an example, increased [Na2þ]i
has been observed during ischemia2–5 and abnormally high [Na2þ]i was identified as a contributor
to ischemia-reperfusion injury. Increase of [Na2þ]i has also been observed in different models of
heart failure (HF).6–9 HF is characterized by a global dysregulation of Ca2þ homeostasis10: increased
[Na2þ]i has been suggested to contribute to altered Ca
2þ handling, which in turn is the main
determinant of the altered contractility and arrhythmias in HF. In this pathological setting,
intracellular Na2þ overload and Ca2þ overload go hand in hand and may constitute a vicious circle.
[Naþ]i not only controls contractility and arrhythmogenicity but also regulates cardiomyocyte
energetics via control of mitochondrial function: Na2þ overload may also contribute to energetic
insufficiency and excessive production of ROS in cardiac diseases. For all these reasons, every
therapeutic attempt aimed at normalizing Ca2þ homeostasis without addressing Na2þ overload is
destined to fail. Actual therapeutic options for heart failure and other cardiac diseases mainly affect
Ca2þ homeostasis and are incapable of reducing arrhythmogenesis and ameliorating contractile
function of diseased hearts. Besides the direct electrophysiological effects, the possible global
benefits of the inhibitors of Naþ channels and carriers, are therefore of utmost interest and are being
investigated in many disease settings.11 This review will focus on the regulation of [Na2þ]i in healthy
myocardium and on its alterations in cardiac diseases such as heart failure and hypertrophic
cardiomyopathy. Moreover, we will review the evidence supporting novel therapeutic options aimed
at normalizing Na2þ homeostasis in different cardiac diseases and their relevance for the clinical
management of cardiac patients.
MEASURING [NA1]I
The capability of measuring intracellular [Naþ]i and its variations in response to pathological changes
of cell function is essential to understand the role of Naþ in the heart. Early approaches to [Naþ]i
measurement involved the use of Naþ selective microelectrodes,12 which are quantitatively precise but
require direct probing of the desired cell with an impaling electrode, limiting its use in contracting
tissue. Recently, the use of Naþ selective fluorescent indicator dyes has become the approach
of choice.
Up to 2011, the most widely used Naþ indicator was SBFI,13 which has been used both in single
cells4 and in intact myocardium.14 The dye is intrinsically ratiometric, being similar to the Fura-2 Ca2þ
dye and allows calculation of the actual [Naþ]i under different conditions. Its versatility is increased
by the possibility to load intact cells and tissue with the membrane-permeant acetoxymethyl-ester
form of the dye. However, SBFI used UV wavelength for excitation, making it unsuitable for use in
some applications and in confocal microscopy. Naþ dyes excited by blue light have been recently
developed to be used in confocal systems and in all largely available fluorescence microscopes.
CoroNa Green15 suffered from a low light yield and a low signal stability. More recently,
Asante-Natrium Green I and II dyes have been developed and employed in a number of studies on
cardiac cells,16,17 with outstanding results in terms of stability and signal intensity. The introduction
of Asante-Natrium Green dyes is rendering [Naþ]i measurement available to all labs due to its
remarkable ease of use. However, green dyes are not intrinsically ratiometric, rendering quantitation
of [Naþ]i more difficult.
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[NA1]I REGULATION IN THE HEALTHY CARDIOMYOCYTE
[Naþ]i is maintained and regulated by a dynamic equilibrium of Na
þ influx and efflux, mediated by a
number of channels and transporters. The influx of Naþ into the myocyte occurs via multiple pathways,
including Naþ channels, Naþ/Ca2þ exchanger (NCX) and Naþ/Hþ exchanger (NHE). The efflux of
Naþ from the cell to the extracellular medium can occur in some conditions through the NCX (acting in
“reverse mode”) but is largely carried out by the Naþ/Kþ pump (NKA), which can act against Naþ
electrochemical gradient at rest. Additionally, [Na2þ]i is in equilibrium with Na
þ concentration within
subcellular organelles, in particular the mitochondria, which can in turn contribute to [Na2þ]i
modulation in disease conditions. We will now focus on the role of these influx and efflux pathways
in the normal heart. A cartoon describing Naþ homeostasis in the healthy cardiomyocyte is shown
in Figure 1.
Na1 channels: peak and late Na1 current
When electrotonic propagation from the neighboring cells depolarizes the cell membrane to reach the
threshold for Naþ channel voltage-dependent activation, a large number of channels open giving rise
to a huge depolarizing current (,20–30 nA/pF at peak), which determines the upstroke phase of the
AP. Therefore, the principal role of Naþ channels is to allow the AP to initiate and permit propagation of
the AP throughout the myocardium. This current is generally short lived because the intrinsic time-
dependent inactivation of Naþ channels determines their fast closure at the beginning of AP plateau.
However, since the current is very large, a non-negligible amount of Naþ is transferred inside the
cytosol at each activation. Their contribution to [Naþ]i is obviously directly dependent on the rate of
activation: the higher the heart rate, the larger the total amount of Naþ entering through the Naþ
channel. The most represented isoform of Naþ channel in the heart is the so called “cardiac” Naþ
channel NaV1.5 (SCN5a gene), which has a relatively low affinity for the selective blocker Tetrodotoxin
(TTX). However, recent work identified other isoforms of Naþ channels in the heart, in particular
neuronal isoforms such as NaV1.1, NaV1.3 and NaV1.7,19 which are all largely more sensitive to TTX.
Meier et al. found that neuronal channels, despite contributing for only 10% to total peak Naþ current,
have a high density in the membrane of t-tubules and may thus be important for t-tubular propagation
of the AP.20 However, selective inhibition of neuronal isoform in the heart with TTX at low concentration





















































Figure 1. Naþ homeostasis in the healthy cardiomyocyte. Cartoon showing the cellular and molecular
determinants of Naþ homeostasis in healthy cardiac cells and their role in the regulation of Ca2þ handling. Note
that yellow arrowsmark Naþ fluxes while blue arrows indicate Ca2þ fluxes. Representative APs from reference 18,
representative Ca2þ transient and force twitch from Coppini et al.17
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excitation-contraction coupling in the cardiomyocyte.21 These investigations are made difficult by the
fact that, in stimulated preparations (such as isolated myocytes), the sodium channel might not be
necessary for cell contraction since the electrical stimulation might also activate the calcium channel
directly.22 Therefore, the exact role of neuronal Naþ channels in the normal heart remains to be
clarified.
Several experiments pointed out that inhibition of the Naþ current with TTX not only reduces the
maximal upstroke velocity of the AP but also shortens the plateau: these observations mean that a
sustained component of Naþ current is somewhat involved in determining the balance of inward and
outward currents that influence AP plateau.23 Two main mechanisms underlie the sustained
component of Naþ current:
1) “Window currents”, i.e. steady state Naþ currents that are present in a voltage interval (230 to
250mV) where channel activation is still possible and channel inactivation is incomplete,
so that a number of inactivated channels can recover from inactivation and immediately
reopen.24,25 Window currents are not largely represented in normal cardiac myocytes26,27
but may be favored by a prolonged repolarization. Moreover, mutations of the SCN5a
gene associated with Long QT Syndrome Type 3 (LQT3) are associated with increased window
Naþ currents.28
2) “Late Naþ current (INaL)”, i.e. TTX-sensitive Na
þ current that can be recorded outside the
window voltage range. Such currents can be recorded from several types of normal cardiac
cells from different species, such as rabbit and human atrial myocytes,29,30 ventricular
myocytes from dog, guinea pig and human,17,31,32 purkinje fibers33,34 and sinus node cells.35 In
normal myocytes, INaL is generally very small (30 pA at 0mV) but it may be enhanced 3 to 5 fold
in pathological conditions (see below).36 INaL has been demonstrated to be brought about by
the same Naþ channels that are responsible for the peak current, i.e. NaV1.5. Indeed, when
only NaV1.5 channels are re-expressed in cell vectors, INaL can be recorded.
37 However, a
recent work pointed out that 44% of the late sodium current in cardiac myocytes from dog
ventricle is due to non-cardiac-type Naþ channels, such as neuronal isoforms NaV1.1 or NaV1.3
or skeletal muscle isoform NaV1.4.38 Single channel studies demonstrated that two
mechanisms are involved in determining INaL: (i) burst openings, which undergo
voltage-dependent inactivation and (ii) scattered openings, which inactivate extremely slowly
and therefore are able to determine a truly “background” Naþ current. The first mechanism is
the most represented in the human.37 INaL is also strongly rate dependent, in that it is reduced
at faster rates of activation, suggesting inactivation and incomplete recovery of the current.34
Albeit very small when compared to peak current, INaL can significantly contribute to determine
[Naþ]i since its duration is several orders of magnitude longer. During a single AP, a normal INaL
may increase the amount of Naþ flowing into the cell by 50% on top of the inflow occurring
during the AP upstroke. As discussed later, this is of utmost importance in conditions where
INaL is increased and its contribution to the total Na
þ inflow increases significantly.
In summary, the total amount of Naþ entering the cell through the Naþ channels is essentially
proportional to the rate of activation and to the density of INaL.
Na1/Ca21 exchanger (NCX)
NCX employs the energy provided by Naþ entering the myocyte following its electrochemical gradient
to transport Ca2þ outside the cell. It is essentially aimed at maintaining a regular Ca2þ homeostasis by
allowing the excess of Ca2þ to flow out of the cell against its electrochemical gradient.39 In fact, NCX is
the major outflow pathway for Ca2þ and is crucial to maintain an equilibrium between Ca2þ entering
the cell through the Ca2þ channel and Ca2þ leaving the cell via the exchanger, which must be equal in
steady-state conditions. Rate and function of the NCX depend on the intracellular and extracellular
concentrations of both Naþ and Ca2þ and are also influenced by the membrane potential. At negative
resting potentials, when most of the Ca2þ outflow occurs, the electrochemical gradient of Naþ and
Ca2þ favors the “forward” mode of the NCX: three sodium ions are brought inside the cell to extrude a
single Ca2þ with a net inflow of one positive change. If Ca2þ inside the cell increases for any reason,
such as an increase of Ca2þ current, so does the activity of the NCX, thereby increasing the amount of
Naþ flowing into the cell through the exchanger.40 Moreover, the activity of NCX can be reduced by
decreased pH and potentiated by ATP: in ischemic conditions, when pH and ATP are relatively lower,
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NCX activity can be seriously impaired.41,42 Though NCX mainly operates in the forward mode, at
potentials positive to the NCX reverse potential (, 2 10mV), the exchanger can also operate in the
reverse mode, producing entry of calcium ions coupled to outflow of Naþ. This phenomenon however
is likely to play a minor role in the healthy myocyte: in fact, though membrane depolarization during
upstroke and plateau could potentially support reverse mode, the concurrent increase of intracellular
[Ca2þ] due to Ca2þ-induced Ca2þ-release from the SR antagonizes Ca2þ inflow through the NCX. In
conditions where [Naþ]i is higher and Ca
2þ release from the SR is reduced NCX reverse mode may play
an increased role, as discussed later.
Na1/H1 exchanger (NHE)
NHE is also capable of exploiting the energy of Naþ gradient to pump Hþ out of the cell by letting Naþ
flow into the cell.43–45 When pH is reduced, the activity of NHE increases in order to bring back pH to
normal levels, making the NHE one of the main molecular modulators of cellular pH. Protons directly
stimulate the exchanger, but NHE has been shown to be modulated by the intracellular signaling
cascade mediated by a number of hormones, neurohormonal agonists and growth factors.46 In
conditions of intracellular acidosis, NHE can significantly contribute to increase Naþ entry and [Naþ]i
within the myocyte.
Na1/K1 ATPase (NKA)
Naþ removal through the NCX is non-relevant in normal conditions, therefore the main mechanism
able to pump the excess of intracellular Naþ out of the cell is the NKA.47 NKA is essential to maintain
the gradients of Naþ and Kþ across the membrane and to allow myocardial excitability. Using the
energy liberated by the hydrolysis of ATP, the NKA is able to extrude 3 intracellular Naþ ions while
bringing 2 extracellular K ions inside the cytosol, thus moving one net charge per cycle. The NKA is
characterized by two major subunits, a and b: the a subunit features the binding site for ATP, Kþ, Naþ
and cardiac glycosides, while the b is essential for a proper membrane localization and insertion.
Different a subunit isoforms with different affinity for ATP and ions exist in the heart and their relative
expression can be modulated by cardiac diseases.47 Interestingly, the rate of NKA can be actively
modulated by a small membrane bound protein similar to phospholamban (the main modulator of
sarcoplasmic reticulum Ca2þ ATPase –SERCA-), called phospholemman (PLM). PLM, like
phospholamban, is abundant in the heart and can be phosphorylated following activation of
b-adrenergic cascade.48 When PLM interacts with the NKA, it reduces the activity of the a subunit,
ultimately reducing Naþ extrusion rate. This has been demonstrated via phospholemman knock-out in
cardiac cells, which led to an increase of NKA activity of the same extent as maximal b-adrenergic
stimulation.49 These observations suggest that PLM, like phospholamban, detaches from the NKA
when phosphorylated by protein kinase A, relieving the specific inhibition.
Mitochondrial Na1 outflow and inflow mechanisms
The main Na2þ efflux mechanism from the cytosol to the mitochondria in the cardiac myocyte is the
mitochondrial Naþ/Hþ exchanger (mNHE).50 The electron transport chain leads to extrusion of protons
from the mitochondrial matrix to the cytosol. The mNHE senses the excess of protons on the cytosolic
side of mitochondrial membrane and brings back Hþ ions into the matrix while extruding Naþ ions
from the mitochondria. From this observation stems the assumption that mitochondrial [Naþ] is around
2 times lower than cytosolic [Naþ] in the intact cell, an assumption that has been experimentally
confirmed in isolated mitochondria and permeabilized myocytes.50 In line with this observation,
metabolic inhibition, via reduction of the activity of the electron transport chain, abolishes the net flow
of Naþ across the mitochondrial membrane and leads to an equal [Naþ] in mitochondria and cytosol.
Under normal conditions, it is unlikely that mitochondria contribute substantially to the regulation of
[Naþ]i. However, in conditions of increased metabolic activity, due to the higher pH gradient across the
mitochondrial membrane, the increased activity of the mNHE could actually lead to transient changes
of [Naþ]i.
The major mechanism involved in Naþ influx to the mitochondria is the mitochondrial Naþ/Ca2þ
exchanger (mNCX). Like the sarcolemmal NCX, mNCX is electrogenic and transports 3 sodium ions from
the cytosol to the mitochondrial matrix while extruding a single Ca2þ from the mitochondrion to the
cytosol.51–55 What provides the driving force for such an exchange given the fact the [Na2þ] gradient
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across the mitochondrial membrane is relatively small? Active mitochondria have a very large
membrane potential with inward direction, ranging from2150mV to2180mV. This large DV provides
the driving force for mNCX function in the forward direction. Interestingly, the mNCX never reaches the
equilibrium in the intact cell: considering [Naþ]i ¼ 8mM, mitochondrial [Naþ] ¼ 5mM and cytosolic
[Ca2þ] ¼ 300nM (average values for an active myocyte), mitochondrial [Ca2þ] would be as low as 1 nM
at equilibrium.56 However, the measured mitochondrial [Ca2þ] in the intact active myocardium is
usually above 150 nM.57 There are multiple reasons explaining why the mNCX does not operate at
equilibrium: (i) the Ca2þ uniporter continuously brings calcium ions inside the mitochondrion following
the favorable electrochemical gradient for Ca2þ across the mitochondrial membrane and (ii) the
activity of mNCX is much lower than that of the Ca2þ uniporter. When the uniporter is blocked by
Ruthenium or by an excess of magnesium, mNCX approaches the equilibrium and mitochondrial [Ca2þ]
is strongly reduced.54,55 Mitochondrial [Ca2þ] is an important regulator of energetics: increased [Ca2þ]
inside the mitochondria activates the enzymes of the oxidative metabolism thus leading to an
increased production of NADH, which in turn increases the function of the electron transport chain,
ultimately determining higher rate of ATP production.56 Ca2þ can also directly activate the
macromolecular components of the electron transport chain.58 mNCX can play a significant role in
regulating mitochondrial [Ca2þ] and thus cardiomyocyte energetics. Increased [Naþ]i leads to
increased influx of Naþ to the mitochondria via the mNCX, accompanied by the concurrent extrusion of
Ca2þ, ultimately resulting in lower mitochondrial [Ca2þ] and thus decreased energetics. This
phenomenon may be relevant in disease conditions where [Naþ]i is elevated (see below).
NA1 REGULATION IN HEART FAILURE (HF)
HF involves a large number of pathophysiological pathways occurring at the level of the single
myocyte. Depending on the model employed, some mechanisms may be different but there is a
general consensus on the presence of two main features: (i) electrophysiological alterations leading to
increased rate of “cellular arrhythmias” and (ii) abnormalities of excitation-contraction coupling (ECC)
leading to contractile dysfunction. Abnormalities of Naþ fluxes and regulation of intracellular [Naþ] are
likely involved in both. Numerous reports from animal models and human samples agree on a general
increase of [Naþ]i in the presence of HF.
6–8 Increased [Naþ]i may have important deleterious
consequences on arrhytmogenesis, contractility and energetics. We will now discuss the mechanisms
involved in Naþ dysregulation in heart failure and the possible therapeutic role of pharmacological
modulation of Naþ fluxes and homeostasis. A cartoon depicting Naþ regulation in HF is shown
in Figure 2.
Abnormal Ca21 handling in heart failure
In order to understand the implications of abnormal Naþ homeostasis in HF we have to keep in mind
the large Ca2þ dysregulation occurring in HF myocytes. Most models of HF, including human, are
characterized by decreased SR Ca2þ- ATPase (SERCA) expression and upregulation of NCX expression
and function (Figure 3). On the other hand, Ca2þ current is generally unmodified.61 Phospholamban
(PLB) is the major modulator of SERCA function and its expression is typically unaltered in HF,62,63 with
decreased phosphorylation. The subsequent increase of PLB:SERCA ratio, coupled with the lower PLB
phosphorylation, enhances the inhibitory effect of PLB on SERCA, contributing to lower SERCA function
in HF. Decreased SERCA activity, by slowing down Ca2þ reuptake to the SR, allows more Ca2þ to be
extruded via the NCX; coupled with the increased NCX expression64 this results in a net loss of cell Ca2þ
and contributes to the reduction of SR Ca2þ load in HF.65 Another contributor to the lower SR Ca2þ
content in HF is the increased diastolic leakage of Ca2þ from the SR, which is determined by the
hyper-phosphorylation of ryanodine receptors (RyRs) by protein-kinase A (PKA) and/or Ca2þ-
Calmodulin dependent protein kinase-II (CaMKII).66 CaMKII activity is increased in HF, and
CaMKII-dependent phosphorylation of RyR enhances Ca2þ spark frequency and thus spontaneous
diastolic SR Ca2þ leak,67 making it one of the leading pathway causing contractile dysfunction and
arrhythmogenesis in HF. Enhanced NCX function, combined with the higher probability of spontaneous
Ca2þ release from the SR, contributes directly to arrhythmogenesis via delayed-afterdepolarizations
(DADs). When a large spontaneous Ca2þ release event occurs during diastole giving rise to a
generalized Ca2þ wave, part of the released Ca2þ is extruded through the NCX, which generates an
inward current that depolarizes the membrane (i.e. a DAD). If large enough, a DAD may reach the
threshold for a premature AP, giving rise to a premature activation that can propagate through the
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myocardium, triggering sustained arrhythmias. As explained below, abnormal Naþ homeostasis may
further increase the risk of arrhythmias in HF with multiple mechanisms.
Alterations of late Na1 current in HF
Increased [Naþ]i in HF may be due to increased Na
þ influx or decreased Naþ efflux. Early studies
suggested that an excess of Naþ influx is the major contributor to Naþ overload and the main source of
the increased Naþ entry is the enhanced “late” or “persistent” Naþ current.7,8 As explained before, a
component of Naþ current with slow or incomplete inactivation can be measured in normal human and
animal cardiac myocytes.26 However, acquired and primary cardiac diseases are commonly
characterized by abnormally large INaL. Enhancement of late Na
þ current has been identified in many
models of disease and may contribute to their pathogenesis: besides classical LQT3 syndrome, which
is due to Na þ channel mutations,68 increase INaL was also found as a consequence of ankyrin B
mutations (LQT4 syndrome)69 and caveolin-3 mutations (LQT-CAV3),70 suggesting that the altered
function of proteins linked to the Naþ channel can affect its function in a way similar to its own
mutations. Moreover, abnormally large INaL was found in cells from hearts of patients affected by end
stage HF,26,71 in animal models of HF72–74 and following myocardial infarction.74 Hypoxia,75 oxygen
free radicals (H2O2),
76 ischemic metabolites (like oxidized lipids)77 and nitric oxide (NO)78 have been
shown to rapidly and directly increase INaL in experimental conditions, suggesting that peroxydation or
nitrosylation of channels may directly alter their inactivation kinetics. Moreover, increased Ca2þ
-Calmodulin79 and calmodulin kinase II (CaMKII) activity,27 both common features of myocardial
remodelling in HF, have been shown to increase INaL. Recent evidence identified CaMKII-mediated
phosphorylation of cardiac Naþ channels at multiple sites is the main regulator of Naþ channel
inactivation.80 Increased levels of phosphorylation at those sites may therefore be the main
responsible for the enhancement of INaL in HF and other diseases. The effects of oxidative stress on INaL
also seem to be mediated by enhanced CaMKII-mediated phosphorylation due to the intrinsically
active oxidized CamKII.81 From a molecular standpoint, enhanced INaL in HF is mediated by an increase
of bursts and scattered late openings in single NaV1.5 channels,37 i.e. the same mechanisms found in
normal myocytes, although with higher gating rates. All this suggests that in HF, INaL enhancement is












































Figure 2. Naþ homeostasis in heart failure. Cartoon showing the cellular and molecular determinants of
abnormal Naþ homeostasis in HF cardiac cells and their role in determining the dysfunction of Ca2þ handling.
White thick arrows mark the changes occurring in HF with respect to control cardiomyocytes. The thickness of
yellow and blue arrows has been changed to match the relative changes of Naþ and Ca2þ fluxes in HF.
Representative AP from reference 18, representative Ca2þ transient from Beuckelmann et al.59 and force twitch
from Sossalla et al.60
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in a rat model of pressure overload-induced hypertrophy and failure it was shown that the increased
INaL is associated with a large up-regulation of neuronal Na
þ channels (Nav1.1, Nav1.3, and Nav1.6) in
the ventricle.82
Whatever the reason of INaL enhancement, this condition is always associated with a prolonged
repolarisation causing a remarkable increase in AP duration,72,83 with increased rate-dependent AP
shortening and temporal variability of AP duration.71,84 AP prolongation leads to reduced repolarisation
reserve and therefore increased incidence of early afterdepolarizations (EADs, i.e. premature
depolarizations occurring during the plateau phase) and potentially fatal arrhythmias.85 Previously
mentioned cardiac conditions, including HF, are all characterized by increased susceptibility to
perturbations of repolarisation (e.g. drugs blocking Kþ currents or electrolyte imbalances) and overall
increased risk of arrhythmias. INaL is an inward current occurring during action potential plateau, when
the membrane potential is sensitive to small current changes since the stabilizing effect of IK1 is absent.
From this stems the marked slowing effect of increased INaL on the rate of repolarization. A slower
Figure 3. Electromechanical dysfunction and Naþ dysregulation in HCM. All panels modified from Coppini et al.17
(A) Superimposed representative action potentials recorded during stimulation at 0.2Hz from HCM and control
cardiomyocytes. (B) Representative recording from an HCM cardiomyocyte paced at 0.2Hz, showing EADs. Blue
arrows mark EADs. Black lines mark stimuli. (C) Representative INaL traces from control and HCM cardiomyocytes
reciorded during voltage-clamp (voltage protocol in inset). (D) Representative superimposed Ca2þi transients
recorded in current-clamp mode while eliciting action potentials at 0.2Hz in control and HCM cardiomyocytes.
(E) Continuous recordings of Ca2þi transients elicited at 0.2Hz, 0.5 Hz and 1Hz frequency of stimulation, from a
control (above) and an HCM (below) cardiomyocyte, highlighting the increased diastolic [Ca2þ] upon increase in
frequency. (F) Superimposed normalized calcium transients induced by rapid exposure to caffeine, highlighting
the slower decay rate in HCM cardiomyocytes and suggesting slower NCX mediated Ca2þ extrusion. (G) Current
density (NCX current) recorded during the caffeine transient is plotted against [Ca2þ]i during the decay phase of
the transient. Each curve is linearly fitted to calculate the [Ca2þ]i level at which NCX current is 0. The
representative superimposed traces are derived from the examples in a. In this example, NCX equilibrium is
reached when [Ca2þ]i is 141 nM in the control cardiomyocyte and 231 nM in the HCM cardiomyocyte. This
suggests an increase of intracellular [Naþ] in HCM cells.
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phase 3 repolarization is a strong predictor of arrhythmic risk,86 likely because it prolongs the time
spent in partial refractoriness (the so called “vulnerable window”). The increased rate of EADs in the
presence of increased INaL is likely a direct consequence of the resulting APD prolongation. Indeed,
prolonged plateau phase allows calcium current (ICaL) to recover from inactivation and reactivate, thus
eliciting the postdepolarization. Prolongation and instability of repolarization in HF is also caused by
other electrical abnormalities such as reduction of Kþ currents.87,88 Due to the reduced repolarizing
currents, the effects of INaL prolongation are more deleterious in HF than in control myocytes.
26 Thus
even a minor inhibition of Kþ currents would result in a severe AP prolongation: INaL thus contributes to
the increased susceptibility to AP prolonging agents in HF (i.e. reduced repolarization reserve),
contributing to drug-induced pro-arrhythmia. So far we have discussed only the potential deleterious
electrophysiological consequences of INaL augmentation in HF; however, the most severe
consequences of the increased INaL are associated with intracellular Na
þ overload. The total amount of
Naþ ions entering the cell through Naþ channels is a function of the current amplitude multiplied by its
duration. Though the amplitude of INaL is small, it lasts for a very long time when compared to peak
current, leading to an increase in Naþ influx ranging from 50% to 100% of peak INa at each activation.
71,
89 Thus, INaL may be the main responsible factor for the increased [Na
þ]i observed in failing myocytes.
7
Alterations of NCX and NHE in heart failure
In addition to the excess of Naþ entering the cell via Naþ channels, increased [Naþ]i in HF may also rely
on enhanced Naþ entry through the NCX or the NHE. As mentioned above, NCX is upregulated in HF
and thus can potentially cause increased Naþ entry, especially if combined with the increased cytosolic
[Ca2þ], which is often seen in failing myocytes due to the increased leakage from the SR. However, the
contribution of the increased NCX function to the higher total [Naþ]i in HF appears to be minimal,
6 for
two main reasons: (i) the absolute of Naþ ions entering via the exchanger is relatively low and (ii) the
increased forward mode activity of the NCX is counterbalanced by an increased reverse mode (see
below), which may become relevant in HF. NHE instead is likely to play a more significant role;
Baartscher et al.9 reported that in a rabbit HF model, the increased [Naþ]i can be inhibited by blocking
the NHE with cariporide. The importance of this mechanisms is confirmed by several reports showing
attenuated development of heart failure and related myocardial dysfunction when NHE inhibitors are
used.45,90,91 NHE activity may be increased in HF as a consequence of energetic imbalance leading to
intracellular acidosis requiring an increased function of the sarcolemmal proton exchanger.
Alterations of NKA in heart failure
On top of the increased Naþ influx, decreased Naþ efflux may contribute to increased [Naþ]i in HF.
Several HF models are characterized by decreased global expression or shift in the isoforms of NKA.91
Most of the studies however have been done on tissue homogenates and may reflect changes of
non-cardiomyocyte protein levels.92 Only a few studies of NKA function have been performed in HF
myocytes, and the results are contradictory: in a model of rat post-myocardial infarction HF a reduced
activity was reported,93 while myocytes from a dog model displayed unaltered maximal NKA pump
current.94 Unaltered pump rate with similar Naþ affinity was also reported in a rabbit HF model6 and
found that both the maximal Naþ transport rate and the NKA affinity for internal Na þ were not altered,
despite the reduced NKA expression in ventricular myocytes.92 The presence of unaltered function
despite less protein count suggests that NKA activity is regulated differently in HF. Indeed, in HF rabbit
myocytes expression of phospholemman (PLM) is reduced,92 determining lower PLM:NKA ratio;
combined with the higher PLM phosphorylation, this results into less overall inhibition of NKA by PLM,
explaining the maintained pump function. Similar changes of PLM expression and phosphorylation
were also observed in human HF.92
Effects of increased INaL and [Na
1]i on cardiomyocyte function
The previous observations on a number of HF models highlight the limited role of NCX and NHE in
determining the increased Naþ entry and the absence of NKA functional alterations reducing global
Naþ efflux. Therefore the major contributor to the increased [Naþ]i in HF is the increased Na
þ entry via
the late Naþ current. AS detailed above, [Naþ]i and [Ca
2þ]i within the myocyte are closely interwoven
through the NCX, the major Ca2þ-extrusion mechanism. [Naþ]i is notably the main determinant of the
overall equilibrium potential of the exchanger (ENCX). An increased [Na
þ]i determines a negative shift of
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ENCX, causing less Ca
2þ extrusion during diastole (decreased forward mode activity) while causing
more Ca2þ influx (increase reverse-mode operation) during the early phase of the action potential,
when membrane voltage is above 0mV.17 Thus, INaL enhancement and the consequent higher [Na
þ]i
may cause intracellular Ca2þ content to rise substantially due to the combined effect of decreased
Ca2þ extrusion and increased Ca2þ entry. [Ca2þ]i overload due to enhancement of INaL is very similar to
the effects of Naþ/Kþ pump inhibition by digitalis,95 which leads to increased [Naþ]i due to reduced
Naþ efflux.
[Ca2þ]i overload brings about a number of short- and long-term changes of myocardial function.
96,97
On the short-term, [Ca2þ]i overload leads to generation of delayed afterdepolarizations (DADs) and the
resulting “triggered” arrhythmias (see above). Indeed spontaneous Ca2þ release from the SR through
RyR channels is facilitated by [Ca2þ]i overload and higher SR Ca
2þ levels.98 NCX translates the resulting
Ca2þ waves into premature depolarizations. In HF, where the RyR is leaky and NCX is overexpressed,
the effects of increased [Naþ]i and the resulting [Ca
2þ]i overload in determining arrhythmic events are
greatly enhanced.
Ca2þ overload may also contribute to the slower repolarization in HF and thus affect the higher
rate of early-afterdepolarizations (EADs). Indeed increased sub-sarcolemmal Ca2þ during the
action potential plateau may reduce Ca2þ-dependent Kþ repolarizing currents (such as IK1),
99
prolonging repolarization. In cardiac tissue, most EADs are preceded by abnormal Ca2þ
transients, highlighting the role of [Ca2þ]i overload in the generation of arrhythmias related to
prolonged AP.100
Sustained [Ca2þ]i overload during diastole directly impairs the relaxation rate of the myocardium,
determining diastolic dysfunction in HF and cardiac hypertrophy. Increased INaL and [Na
þ]i may
significantly contribute to diastolic dysfunction in cardiac diseases with different mechanisms:
1) Increased AP duration renders Ca2þ release longer and prolongs contraction: inhomogeneous
prolongation of APD will increase variability of twitch duration in the ventricle, leading to
uncoordinated relaxation.
2) Increased diastolic [Ca2þ]i leads to slower and incomplete myofilament inactivation and
relaxation; this phenomenon is extremely more pronounced at high pacing rates, due to a
more marked cytosolic Naþ and Ca2þ overload. At high pacing rates, the extreme [Ca2þ]i
overload extending throughout the entire diastolic period may severely impair relaxation,
effectively provoking contractures.101
3) Spontaneous Ca2þ releases induced by [Ca2þ]i overload generate diastolic after-
contractions that further impair and delay relaxation.102
A further consequence of the impaired diastolic function determined by enhancement of INaL and
[Naþ]i overload is a reduction of myocardial blood flow perfusion. Due extrinsic compression of blood
vessels by the contracting muscle,103 myocardial coronary flow is limited during systole, and reaches a
maximum during the initial relaxation phase. In HF, the early diastolic phase (isovolumic relaxation) is
slower, due to the delayed decay of cytosolic Ca2þ transient, myofilament force and wall stress.
Increased INaL may play a significant role in that phenomenon. Indeed, experimental INaL enhancement
by ATX-II determines reduced coronary blood flow83 and pharmacological block of INaL ameliorates
perfusion.101
The increase of [Naþ]i and the resulting [Ca
2þ]i overload may also affect cardiomyocyte energetics.
As detailed above, mitochondrial Ca2þ is essential to maintain cell energy balance. In presence of high
cytosolic [Naþ], mitochondrial NCX increases Ca2þ extrusion from the mitochondrial matrix, lowering
mitochondrial [Ca2þ]. This results in reduced ATP production, thus creating a mismatch between ATP
consumption and production.104 Additionally, high [Naþ]i decreases the extrusion of H
þ through the
NHE; thus, INaL enhancement may also lead to cellular acidosis in HF, with severe effects on cell
metabolism.105
Finally, chronically increased [Ca2þ]i due to increased INaL and [Na
þ]i leads to activation of numerous
intracellular signaling pathways: increased activity of PKC, CaMKII and calcineurin not only acutely
affects Ca2þ homeostasis and membrane currents but may also activate transcriptional factors,
ultimately leading to hypertrophic response and accelerating cellular remodelling.106,107 Hyper-
activation of CaMKII can in turn further increases INaL (by phosphorylating Na
þ channels) and [Ca2þ]i
(by increasing SR Ca2þ leakage following RyR phosphorylation),67 creating a vicious circle. In HF and
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hypertrophy, increased CaMKII activity has a pivotal role in supporting a positive feedback loop
between INaL and [Ca
2þ]i overload.
27
In conclusion, increased INaL not only directly affects cell electrophysiology but also alters Ca
2þ
homeostasis with potential consequences for contractile function, cell metabolism and altered cell
signaling leading to hypertrophic response.
NA1 REGULATION IN HYPERTROPHIC CARDIOMYOPATHY
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease,108,109 with a
prevalence in the general population of 1:500, representing a leading cause of sudden cardiac death in
the young109 and a prevalent cause of heart failure and stroke.110 Increased arrhythmogenesis and
diastolic dysfunction are the two main pathophysiological features of this disease.111
HCM is associated with a complex electrophysiological cardiomyocyte remodelling involving multiple
changes in transmembrane currents ultimately leading to susceptibility to ventricular arrhythmias. We
have recently characterized the electrophysiological, Ca2þ handling and contractile abnormalities
occurring in human HCM myocardium as concurrent determinants of diastolic dysfunction and
arrhythmias in this disease.17 We used isolated myocytes and intact trabeculae from myocardial
specimens from the interventricular septum of HCM patients undergoing surgical myectomy, compared
with non-hypertrophic surgical patients. Results of patch clamp studies showed that the action
potential duration (APD) recorded at various frequencies of stimulation was markedly prolonged in
cardiomyocytes from patients with HCM (HCM cardiomyocytes) compared to controls (Figure 3A).
Prolonged APD was associated with prolonged QTc in patients from the HCM group (average
QTc ¼ 470ms). Of note, a recent large-scale study on HCM patients reported that QT prolongation is a
common feature in patients with this disease112 and may be a predictor of clinical outcome. Prolonged
APD led to increased risk of early after depolarisations (EADs),85 which were 6-fold more frequent in
HCM cardiomyocytes than in control cells (Figure 3B). Interestingly, the degree of APD prolongation was
associated with the frequency of ventricular arrhythmias in patients: patients with severely prolonged
APD had a higher frequency of documented non-sustained ventricular tachycardia at 24 h ECG.17 APD
prolongation in HCM cardiomyocytes is determined by an imbalance between inward and outward
transmembrane currents: repolarizing Kþ currents were reduced and L-Type Ca2þ current was
increased. Importantly, we also observed that the amplitude of INaL in HCM cardiomyocytes was larger
compared to control patients, likely contributing to APD prolongation (Figure 3C). APD and ion current
abnormalities determined significant alterations of intracellular Ca2þ handling in HCM cardiomyocytes
(Figure 3D). The amplitude of Ca2þi transients were similar in HCM and in control cardiomyocytes.
Conversely, the kinetics of Ca2þi transient, were significantly longer and intracellular diastolic Ca
2þ
concentration ([Ca2þ]i) was markedly higher in HCM compared to control (Figure 3E). Interestingly,
[Ca2þ]i overload was accompanied by an increased rate of spontaneous Ca
2þ releases from the SR and
DADs in HCM cardiomyocytes, thus contributing to arrhythmogenesis. Additionally, we found a slightly
increased SR Ca2þ content in HCM cardiomyocytes while the rate of Ca2þ extrusion via NCX was
reduced (Figure 3F). In keeping with this observation, we measured a negative shift of the reversal
potential of NCX (ENCX) that suggests increased [Na
þ]i (Figure 3G). Indeed, we reported an increased
[Naþ]i in HCM myocytes, directly assessed by virtue of fluorescence measurements with Asante
Natrium Green 2 Naþ-selective dye. Based on this data, we suggested that in HCM enhanced
INaL-mediated Na
þ influx leads to a sustained increase in [Naþ]i, providing the driving force for an
increased rate of Ca2þ entry trough NCX, which is also overexpressed. However, increased [Naþ]i also
impairs forward-mode NCX function, leading to the observed reduction of Ca2þ extrusion rate during
caffeine exposure and likely contributing to slow down Ca2þ transient decay and increase diastolic
[Ca2þ]i, in combination with SERCA down regulation. The observed abnormalities of excitation-con-
traction coupling resulted in slower relaxation and increased diastolic tension in intact trabeculae
isolated from the same samples. Interestingly, increased activity of CaMKII appears to underlie several
of the observed changes in HCM cardiomyocytes: increased phosphorylation of Naþ channels
determined enhanced INaL,
27,80 while increased RyR phosphorylation caused SR Ca2þ leak and DADs.66
We concluded that, among the several ion channels and EC-coupling protein changes, increase of INaL
and [Naþ]i overload are major contributors to electro-mechanical cardiomyocyte dysfunction, which
may be strongly associated with the increased arrhythmogenesis and diastolic dysfunction observed in
HCM patients. Naþ dysregulation in HCM is described in the cartoon in Figure 4.
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ROLE OF PHARMACOLOGICAL INAL INHIBITION IN CARDIAC DISEASES
Recent work highlighted the emerging role of INaL in the pathogenesis of HF, hypertrophic
cardiomyopathy and other cardiac diseases, making INaL an interesting pharmacological target for
disease management. We have previously highlighted the severe consequences of INaL enhancement
in terms of arrhythmogenesis and contractile dysfunction. INaL inhibition may therefore improve both
electrical and mechanical function of cardiomyocytes in many disease states. Therapeutic INaL
inhibition has been attempted in a number of conditions in which INaL is abnormally enhanced,
including LQT3, acute ischemia, experimental oxidative stress and heart failure72,101,113– 116: in all these,
INaL block determined shortening of APD, reduced temporal and spatial variability of repolarization and
abolished EAD occurrence, highlighting a clear antiarrhythmic effect. Since INaL is carried by cardiac
Naþ channels, all drugs that interact with NaV1.5 channels affect INaL. Indeed late Na
þ current is
inhibited by all classical Naþ channel blockers, comprising not only experimental agents such as Cd2þ,
Tetrodotoxin (TTX) and Saxitoxin (STX),26,71 but also clinically employed drugs. These include: (i)
flecainide,117,118 which proved effective in shortening APD and reducing EADs in models of Long QT
Type 3 (LQT3) syndrome induced by NaV1.5 mutations; (ii) mexiletine,113,119 which demonstrated a clear
ability to prevent the occurrence of arrhythmias induced by experimental APD prolongation and
reduced dispersion of repolarization in LQT3120; (iii) lidocaine121 and quinidine,122 which effectively
blocked genetically or experimentally enhanced INaL. However, all of these drugs exert an effective INaL
block only at relatively high concentrations; at such concentrations, classical Naþ channel blockers
also strongly inhibit peak Naþ current with great effects on myocardial excitability and conduction
velocity. Under these conditions, the potential anti-arrhythmic effects of INaL block may be overcome by
the pro-arrhythmic consequences of the slower conduction.122 Among classical Naþ channel blockers,
flecainide displays the highest selectivity for the late component of Naþ current117; however, the
elevated pro-arrhythmic risk associated with flecainide use in structural heart diseases123,124 prevents
its clinical use in conditions where INaL is enhanced (heart failure, cardiomyopathies). Indeed
flecainide, which inhibits peak Naþ current other than INaL, causes significant conduction delay
125 and
has been associated with increased mortality in post-myocardial infarction patients126: conduction
slowing (induced by INa peak block) combined with reduced refractoriness (due to shorter APD via INaL


















































Figure 4. Naþ homeostasis in hypertrophic cardiomyopathy. Cartoon showing the cellular and molecular
determinants of abnormal Naþ homeostasis in cardiac cells from HCM patients and their role in determining the
dysfunction of Ca2þ handling and contraction. White thick arrows mark the changes occurring in HCM with
respect to control cardiomyocytes. The thickness of yellow and blue arrows has been changed to match the
relative changes of Naþ and Ca2þ fluxes in HCM vs. control cells. Representative traces from Coppini et al.17
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Amiodarone was shown to have INa blockade capacity as an ancillary effect. Interestingly,
amiodarone effectively blocked INaL in cardiomyocytes from human failing hearts at concentrations as
low as 5mM, i.e. within the therapeutic range of the drug; amiodarone produced almost no effect on the
transient Naþ current at these concentrations.128 These results suggest that selective block of INaL over
peak current may mediate part of the anti-arrhythmic effects of amiodarone and contribute to limit its
pro-arrhythmic toxicity, making it a relatively safe drug also in the presence of structural heart
disease.129 However, amiodarone is far from being a selective agent, in that exerts a potent blockade of
repolarizing Kþ currents (mainly IKr), with potential pro-arrhythmic consequences,
130,131 especially when
assumed in association with other QT prolonging drugs. As detailed above, in presence of severely
increased INaL, the APD prolonging effect of K
þ current blockers is enhanced, raising the risk of
proarrhythmic effects.132,133 From all these observations stems the need of a drug that blocks INaL with
high selectivity.
Developed in the 1990s as a cardiac specific partial fatty acid oxidation inhibitor, ranolazine was first
experimented as a possible anti-anginal compound, with relatively good results. Ranolazine was found
to be safe in humans in doses up to 2 grams/day, and it was effective in reducing symptoms in two
clinical trials on chronic stable angina patients.134,135 It rapidly became clear that the anti-anginal and
anti-ischemic effects of ranolazine were not due to the supposed metabolic effects (which are
negligible at therapeutic concentrations), but rather to its selective blockade of the late sodium current.
Its electrophysiological effects were in fact described in 2004136 Ranolazine exerts an inhibitory effect
on IKr and a slight ICaL block
136; but the main effect was a potent inhibition of INaL with small or no effect
on peak INa within the therapeutic concentration range. Inhibition of IKr is generally considered
pro-arrhythmic. However, in a large scale trial on non ST-elevation myocardial infarction patients,
ranolazine significantly reduced the incidence of ventricular tachycardia137 and was not associated with
QRS prolongation or increased mortality in these patients.138 Recent work showed that ranolazine
inhibits triggered activity and its propagation in pulmonary veins, the main source of atrial ectopies,
and reduces afterdepolarizations in atrial myocardium from surgical patients,139 suggesting that
ranolazine may also play a role in the prevention of atrial fibrillation.140 These observations support the
view that INaL inhibition by ranolazine may be antiarrhythmic, even in the presence of a limited
concomitant block of IKr. INaL, whose density is highly variable among different layers and regions of the
ventricle, strongly contributes to spatial differences in repolarization. INaL inhibition is therefore
associated with a reduced transmural dispersion of repolarization,136 contributing to its anti-arrhythmic
effects. Ranolazine also inhibits other cardiac currents, including ICaL, IKs, IK1, Ito and INCX.
136 However,
except for ICaL, the concentrations of ranolazine required to inhibit these other ion currents are at least
10-times higher than those required to block INaL. Therefore, only inhibition of INaL, ICaL and IKr may
contribute to ranolazine effects at therapeutic concentrations. Recently, a newly developed INaL
inhibitor (GS-458967) was shown to inhibit late current with a higher selectivity as compared with
ranolazine, even at 10-times lower concentrations; GS-458967 effectively reduced experimentally
induced cellular arrhythmias (EADs and DADs).141
We have previously highlighted the multiple deleterious effects of increased INaL on cardiomyocyte
function. INaL inhibition, via reduction of Na
þ influx, antagonizes [Naþ]i elevation, thus preventing
[Ca2þ]i overload secondary to [Na
þ]i overload. The increased [Ca
2þ]i in HF and other disease settings
can be viewed as a compensatory mechanism for contractile dysfunction. However, it appears that the
detrimental consequences of increased [Ca2þ]i (i.e. increased SR Ca
2þ leakage, increased diastolic
tension) prevail over the advantages. Indeed, ranolazine abolished the occurrence of spontaneous
after-contractions and reduced diastolic tension without decreasing contractility in myocytes and intact
trabeculae from human and rat failing hearts.60,115 Reduction of [Ca2þ]i should improve diastolic
function but also impair systolic contraction. Instead, in diseased myocytes ranolazine only reduced
diastolic [Ca2þ]i without affecting neither the [Ca
2þ]i transient amplitude nor SR Ca
2þ content,60
explaining the global amelioration of the contractile profile seen in intact muscle, especially at higher
stimulation rates. The reason why ranolazine is able to differently modulate diastolic [Ca2þ]i and SR
Ca2þis the concomitant reduction of Ca2þ leak from the SR.142 When the lower [Naþ]i leads to
decreased [Ca2þ]i the resulting reduction of leak may improve the ability of the SR to reuptake Ca
2þ,
thus preserving integrity of Ca2þ store.
INaL inhibition has marked cardioprotective effects in conditions of myocardial ischemia, when
increased activity of the NHE leads to increased Naþ influx.143 Inhibition of INaL may improve
intracellular pH homeostasis by allowing a maintained rate of proton extrusion via the NHE. Finally,
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recent observations indicate that INaL inhibition, via amelioration of relaxation and reduction of
end-diastolic pressure, may significantly enhance coronary blood flow, especially in ischemic
conditions.83
In keeping with the favorable mechanical consequences of INaL inhibition, ranolazine, unlike other
anti-ischemic drugs, does not decrease the “double product” of arterial pressure and heart rate which
is a valuable measurement of cardiac overall mechanical work.144 In conclusion, recent evidence
support the assumption that ranolazine markedly improves the contractile efficiency of diseased
myocardium and increases coronary blood flow, independently of changes in cardiac work.
INAL INHIBITION REVERSES ELECTRO-MECHANICAL DYSFUNCTION
IN HYPERTROPHIC CARDIOMYOPATHY
Among the several changes identified in cellular electrophysiology and Ca2þ handling in our recent
study on human HCM cardiomyocytes,17 we found that the increased late sodium current is amenable










































































Figure 5. Late sodium current inhibition reverses electro-mechanical dysfunction in HCM. All panels are modified
from Coppini et al.17 (A) Action potentials at 0.2Hz from an HCM cardiomyocyte before (Basal) and after exposure
to 10mmol/L ranolazine (Ran). (B) Representative trace from a HCM cardiomyocyte in the absence of ranolazine
showing multiple early after depolarizations (EADs), marked by blue arrows. A trace from the same
cardiomyocyte in the presence of ranolazine is shown superimposed in red: the drug abolishes EADs. Black
arrowheads mark stimuli. (C) Superimposed representative Ca2þi transients at 0.2Hz from an HCM
cardiomyocyte (same as A) at baseline and with ranolazine. (D) Trains of Ca2þi transients elicited at 0.2, 0.5, and
1Hz in an HCM myocyte before (left) and following (right) exposure to ranolazine, highlighting reduction of
diastolic [Ca2þ]i. (E) Superimposed caffeine-induced calcium transients in the absence and presence of Ran in a
HCM cardiomyocyte, highlighting the faster time constant (t) of caffeine-induced Ca2þi transient decay,
suggesting higher rate of NCX-mediated Ca2þ extrusion. (F) Effects of ranolazine on intracellular Naþ.
Representative traces of Asante Natrium Green florescence, recorded at stimulation rates of 0.2Hz, 0.5 Hz and
1Hz in the absence (black) and presence (red) of 10mM Ran.
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both in determining APD prolongation and Ca2þ handling abnormalities leading to abnormal
relaxation, INaL inhibition is expected to positively affect both. In control cardiomyocytes, ranolazine
(10mM) did not significantly affect the APD and the effects of ranolazine on the amplitude and kinetics
of Ca2þi transients were negligible. On the contrary, ranolazine significantly reduced APD in HCM
cardiomyocytes (Figure 5A). Consistently, the occurrence of EADs in HCM cardiomyocytes was
approximately halved by the application of ranolazine (Figure 5B). We found that ranolazine 10mM
markedly blocked INaL in HCM myocytes, confirming that the described effects of the drug are
consistent with specific INaL inhibition. In HCM cardiomyocytes, the APD shortening by ranolazine was
paralleled by accelerated rise and decay time of Ca2þi transients, associated with no significant
decrease of Ca2þi transient amplitude (Figure 5C). Ranolazine significantly reduced intracellular
diastolic [Ca2þ]i in HCM myocytes and attenuated the increase in diastolic [Ca
2þ]i following increase in
stimulation rate (Figure 5D). In agreement with these results, we found that ranolazine slightly reduced
SR Ca2þ-load in HCM myocytes and significantly accelerated caffeine-induced Ca2þi transients,
suggesting an increased rate of Ca2þ-extrusion through the NCX upon exposure to the drug (Figure 5E).
The beneficial consequences of INaL inhibition on Ca
2þ handing in HCM cardiomyocytes were mediated
by a marked reduction of [Naþ]i, as confirmed by direct assessment using Na
þ -selective fluorescent
indicators (Figure 5F). Reduced [Naþ]i shifted ENCX back to positive levels, potentiating forward mode
operation of the NCX.
The beneficial effect of ranolazine was finally investigated in intact tissue measuring isometric twitch
tension from intact ventricular trabeculae.17 Ranolazine, speeded up the kinetics of force development
and shortened the overall twitch duration. Further, it significantly diminished the rise of diastolic
tension upon increase in stimulation frequency, without significantly reducing peak isometric (active)
force. According to our results, by reducing [Naþ]i overload, and thus diastolic [Ca
2þ]I, ranolazine has
the potential to improve diastolic function, a cause of symptoms in most HCM patients, and to
indirectly improve myocardial perfusion, thus impacting on functional limitation and quality of life.
Taken together these results highlight the great potential of INaL inhibition for the reduction of
arrhythmias and diastolic dysfunction in HCM patients.
In the long term, the effect on calcium homeostasis is expected to down regulate a number of
remodelling pathways that strictly depend on myocyte driven signalling: this may in turn bring benefit














































































Figure 6. Effects of INaL inhibition in HCM. Cartoon showing the cellular and molecular determinants of the effects
of INaL inhibition in HCM cardiac cells and their role in determining the ameliorated Ca
2þ handling and
contraction in presence of the ranolazine. Red thick arrows mark the changes occurring in HCM in the presence
of ranolazine with respect to the baseline condition. Representative traces from Coppini et al.17 Baseline traces
are black and the corresponding traces in the presence of ranolazine are red.
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hypertrophied myocardium. In particular, reduction of intracellular Ca2þ overload, may lead to
sustained lower CaMKII activity, eventually affecting the functional and structural remodelling of HCM
myocardium, with possible implications for disease progression.145 In keeping with this observation,
ranolazine administration has been shown to reduce the degree of myocyte hypertrophy and interstitial
fibrosis in experimental hypertrophy models.146 Thus, late sodium current inhibition in HCM may be
capable of preventing disease progression towards the end-stage phase, by acting upon one of its
most critical determinants – diastolic dysfunction, myocardial ischemia and fibrosis. In principle, late
sodium current inhibition is the ideal therapeutic strategy for HCM patients, with a wide range of
positive actions, which may have a critical impact on acute symptoms as well as on the natural history
of the disease. The effects of ranolazine on HCM cardiomyocytes and the role of CaMKII are
summarized in Figure 6.
CONCLUSIONS
The numerous ion transport pathways involved in the regulation of [Naþ]i are critical in mediating both
contractile and electrical activity of cardiac myocytes. [Naþ]i regulation and [Ca
2þ]i homeostasis are
highly interdependent, and the delicate dynamic interplay of [Ca2þ]i and [Na
þ]i is deeply impaired in
pathophysiological situations such as heart failure and hypertrophic cardiomyopathy, contributing to
contractile dysfunction and arrhythmogenesis. The progressive clarification of the involvement of INaL in
the pathogenesis of Naþ and Ca2þ overload has rendered this current an appealing pharmacological
target. The most significant advantage of INaL inhibition is its potential to simultaneously target the
consequences of disease-related functional changes (e.g., arrhythmias and contractile dysfunction) as
well as the mechanisms underlying its progression (e.g., myocardial remodelling, ischemia). The
potential therapeutic value of INaL inhibition discussed in this review, in particular in heart failure and
hypertrophic cardiomyopathy, still awaits confirmation from clinical trials. Whereas INaL inhibitors have
a proven efficacy in patients with ischemic heart disease, confirmed by clinical trials, the most attractive
clinical applications of INaL inhibition, heart failure and hypertrophy, remain largely unexplored and
deserve further pre-clinical and clinical investigation.
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